Arcutis Biotherapeutics reports Q3 EPS 6c, consensus 17c

Arcutis Biotherapeutics reported Q3 EPS of 6c, below the 17c consensus, with revenue of $143.92M, slightly above the $142.59M consensus. The company highlighted strong performance and growth prospects, including a potential FDA approval for ZORYVE cream in early 2027 and ongoing clinical trials. CEO Frank Watanabe announced a new awareness campaign with Simone Biles to promote ZORYVE.

Original reporting
Published Nov 4, 2026, 9:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 1:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ARQT
Bearish
high confidence
Mentioned
$ARQT
Relevance
7/10
AlphAI data visualization · based on tipranks.com
Decision brief

The 30-second read

$ARQTBearishMed
01

Why it matters

Earnings miss may trigger short‑term sell‑off, but upcoming FDA decisions and pipeline progress could provide longer‑term upside.

02

Market read

Arcutis' earnings miss is the primary catalyst for near‑term price action; investors will watch upcoming regulatory milestones.

03

What to watch

Potential FDA approval for ZORYVE cream in early 2027 and progress on ARQ-234 trial may offset short‑term earnings disappointment.

Relevance 7/10Novelty 7/10Timing: post-market release

Background

Arcutis Biotherapeutics highlighted its ZORYVE product line and announced a new awareness campaign with Simone Biles.

Company-level read

Ticker impact

$ARQTBearishHigh confidence
Context

Q3 earnings report shows EPS of $0.06 versus consensus $0.17 and revenue $143.92M versus $142.59M, a miss on earnings that may pressure the stock.

Expected impact

likely pressure as the market prices in the earnings miss

Evidence & confidence

The company missed consensus EPS by a wide margin; biotech stocks typically react sharply to earnings surprises.

Market effects

The miss may weigh on the broader dermatology biotech sector as investors compare pipelines.

Limited to US biotech investors; no broader regional effect.

Minimal global impact beyond niche biotech investors.

Counterpoint

If the revenue beat is viewed as a sign of strong demand, the stock could rebound despite the EPS miss.

Key entities

  • Frank Watanabe

    President and CEO of Arcutis Biotherapeutics, provided commentary on earnings and pipeline.

Related articles

$ARQTHighAI 8/10

Arcutis reports trial data on infant eczema treatment candidate

Arcutis Biotherapeutics (ARQT) presented INTEGUMENT-INFANT trial data for ZORYVE cream 0.05% in treating infant atopic dermatitis. The study showed no serious adverse events, with 66.7% of infants reporting itch improvement within 4 hours. The cream is approved for children 2-5 years and is under FDA review for infants 3-24 months, with a decision expected by February 23, 2027.

$ARQTMed

Arcutis (ARQT) Q3 2026 Earnings Call Transcript

Arcutis Biotherapeutics (ARQT) reported Q3 2026 revenue of $143.9M, up 45% YoY, driven by ZORYVE franchise growth. Full-year revenue guidance raised to $535M-$545M. Net income was $8.8M, with cash and securities at $259.8M. The company plans to invest in commercial initiatives for 2027 growth, focusing on dermatology and primary care.

$ARQTMedAI 8/10

TD Cowen raises Arcutis stock price target on Zoryve momentum

TD Cowen raised its price target for Arcutis Biotherapeutics (ARQT) to $40 from $35, citing strong Zoryve sales of $144M and raised 2026 guidance. Revenue grew 11% quarter-over-quarter and 45% year-over-year, with a 91% gross profit margin. The stock trades near its 52-week high at $34.05. Arcutis reported Q3 2026 revenue of $143.9M, beating estimates, but missed profit expectations.